Conference Coverage

Key questions to ask atopic dermatitis patients with sleep complaints


 

FROM REVOLUTIONIZING AD 2021

If you don’t think it’s important to assess for sleep disorders in your patients with atopic dermatitis (AD), think again.

According to Sabra M. Abbott, MD, PhD, professor of neurology at Northwestern University, Chicago, AD is associated with difficulty falling asleep, nighttime awakenings, early morning awakenings, increased daytime sleepiness, decreased sleep efficiency, increased arousals, awakenings, and sleep fragmentation, as well as increased night kicks and nocturnal leg cramps, and a more than twofold increased risk for insomnia.

Sleep disturbance and geriatric age in atopic dermatitis: Is there a link?

During the Revolutionizing Atopic Dermatitis symposium, she offered key questions to ask AD patients who present with sleep complaints:

When do you go to bed? “This does not refer to when you get into bed, but when do you actually go to bed with an intention to go to sleep, outside of watching television or answering emails?” Dr. Abbott said.

How long does it take for you to fall asleep?

Do you wake up in the middle of the night, and for how long? What do you do if you wake up?

When do you wake up in the morning? Is it on your own, or with an alarm clock?

Does this schedule change on nonworkdays?

Do you have daytime impairment? Meaning, do your sleep complaints impact how you function during the daytime?

Do you snore? Meaning, is there concern for sleep apnea?

Do you have uncomfortable sensations in your legs? Are they worse in the evening and improve with movement? These are signs of possible restless legs syndrome.

The Epworth Sleepiness Scale is one self-administered questionnaire to consider using for AD patients with sleep complaints. “This provides patients with several examples of typical scenarios they might encounter during the day and queries whether or not they feel that they could deal with any of those scenarios,” Dr. Abbott said. “A score of greater than 10 indicates that they are sleepy; it’s not just an overall sense of fatigue and decreased energy.”

Other brief self-assessment tools she recommended are the Insomnia Severity Index and the STOP-Bang questionnaire.

Dr. Abbott reported having no financial disclosures.

Recommended Reading

Mepolizumab reduced exacerbations in patients with asthma and atopy, depression comorbidities
Clinician Reviews
Novel oral agent effective in teens with atopic dermatitis
Clinician Reviews
Ruxolitinib cream for atopic dermatitis is in regulatory home stretch
Clinician Reviews
Itch response faster with abrocitinib in trial comparing JAK inhibitor to dupilumab
Clinician Reviews
No link between childhood vaccinations and allergies or asthma
Clinician Reviews
Atopic dermatitis subtype worsens into midlife, predicting poor health
Clinician Reviews
FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.
Clinician Reviews
AD burden may be greater for those with head, neck, face, and hand involvement
Clinician Reviews
FDA gives nod to tralokinumab for adults with moderate to severe AD
Clinician Reviews
Longitudinal course of atopic dermatitis often overlooked, expert says
Clinician Reviews